Gene therapy VGN-R13 for ALS safety and tolerability
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed ALS diagnosis, but it must not be caused by SOD1 or FUS gene mutations.
- Your first ALS symptoms started less than 2 years ago.
- Your lung function test (FVC) is at least 50% of normal for your age, gender, and height.
- You are not currently taking certain strong medications or have not used other ALS drugs or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single injection of SNUG01 into the spinal fluid to see if it is safe and could help people with ALS. It is an early study to check for side effects and how well the treatment works.
This trial tests a new gene therapy called SNUG01 for adults with ALS. It aims to see if the treatment is safe and can slow the disease. You may be eligible if you are diagnosed early (within 2 years) and have good breathing function.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This trial tests a new drug called RAG-21 for people with ALS who have a specific change in their FUS gene. The goal is to see if it is safe and if it can slow down the disease.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.